Pegloticase (Krystexxa): The Last Resort That Actually Works

Somewhere back in your evolutionary history, your ancestors carried an enzyme called uricase. Its job was simple. It broke uric acid down into allantoin, a far more water-soluble waste product that the kidneys flush out without complaint¹. Then the gene broke. Most other mammals still carry a working copy. We do not, which is a large part of why gout is such a stubbornly human problem.

Pegloticase hands the tool back. It is a lab-grown uricase, wrapped in a protective coating that helps it survive in the bloodstream, and once it is circulating it does the work your body stopped doing generations ago. Uric acid gets converted into allantoin and leaves. Not slowed. Not nudged. Cleared.

That is the whole reason this drug exists, and the whole reason it is handled with such care. Every other urate-lowering medicine works around the edges of your chemistry, turning down production or coaxing your kidneys into excreting more. Pegloticase goes straight at the uric acid itself, fast enough that deposits which took years to build finally have room to come apart.

Here is the honest version, and it is not a sales pitch. Pegloticase is not where treatment starts. The American College of Rheumatology strongly recommends against it as first-line therapy². For most people, an oral medicine like allopurinol, started low and raised until serum urate sits below 6 mg/dL, does the job without anyone ever putting a line in your arm³.

Where pegloticase earns its place is at the end of that road. When xanthine oxidase inhibitors, uricosurics and everything else have genuinely failed to reach target, and a person is still having frequent flares or carrying tophi that will not dissolve, the ACR strongly recommends switching to pegloticase⁴. That is the specific job it was built for. Uncontrolled, tophaceous, refractory gout. The gout that other gout patients have not met.

It is just as clearly not for milder disease. If your uric acid is above target but your flares are infrequent, fewer than two a year, and you have no tophi, the guideline strongly recommends against switching to pegloticase⁵. That line is not gatekeeping. It is arithmetic. The risks below only make sense when they are weighed against a genuinely heavy disease burden.

This is the part nobody quite prepares you for. Pegloticase is not something you collect from a pharmacy on the way home. It is an intravenous infusion, given in a clinic or infusion suite by people trained to watch you while it goes in. The trials that established the drug used a dose given every two weeks, and that fortnightly rhythm is still the familiar pattern⁶. Your rheumatologist sets the schedule that fits you.

Plan for the day rather than the hour. There is the drip itself, which runs slowly on purpose, and there is a stretch of monitoring afterwards, because reactions tend to announce themselves during or shortly after the infusion. Many teams give an antihistamine and a steroid beforehand to take the edge off that risk. Most will draw blood to check your uric acid before they start anything.

That pre-infusion blood draw is not a formality, and it is worth understanding why.

Pegloticase is a foreign protein. Your immune system, which is very good at its job, sometimes notices and starts building antibodies against it. When that happens the drug gets swept out of your blood before it can finish its work, uric acid climbs back up, and the odds of a bad infusion reaction climb with it. This is one of the few situations in gout where the number tells you more than the feeling. A uric acid level that has started rising again, measured before the next infusion, is the sign your team watches for that the drug is losing its grip.

For years that was pegloticase's ceiling. Then a randomised trial called MIRROR tested a straightforward idea: give methotrexate alongside it and quiet the immune response before it gets started. The share of people who responded rose from 38.5% on pegloticase alone to 71.0% with methotrexate added, and infusion reactions in that trial fell from 30.6% in the comparison group to 4.2%⁷.

Two caveats, said plainly. Those figures come from a single trial, and they arrived after the 2020 ACR guideline was written, so the guideline does not account for them. But they changed how rheumatologists reach for this drug. Pairing pegloticase with a medicine that calms the immune response is now a common approach rather than an experiment, and it is a fair thing to raise with your specialist before the first infusion rather than after the third.

Here is a piece of this story that deserves more attention than it usually gets. When pegloticase breaks uric acid down, the reaction leaves hydrogen peroxide behind. Most red blood cells handle that without any trouble. Red cells in people with G6PD deficiency, an inherited shortage of a protective enzyme, cannot. The result can be haemolysis, where red cells rupture, and methaemoglobinaemia, where blood loses its ability to carry oxygen properly. Pegloticase is contraindicated in G6PD deficiency, and anyone at higher risk should be screened before starting it⁸.

G6PD deficiency is not rare, and it is not evenly spread. It affects roughly 12% of African Americans⁸. That turns the screening test into an equity question rather than a box on a form, because a step treated as optional gets skipped most often for exactly the people it was designed to protect.

The practical version is short. It is a blood test. It happens once, before you start. Ask whether it has been done, and do not feel awkward asking. Good teams will be glad you did.

The trials that brought pegloticase to market enrolled people whose gout had refused everything else. Over six months, about 42% of those given the fortnightly infusion and 35% of those given it monthly reached the uric acid endpoint. In the placebo group the figure was zero⁶.

Read that honestly and it cuts both ways. Roughly four in ten responded, which means most did not, and that is a hard sentence to write for anyone who has run out of other options. But hold the comparison steady. Nobody on placebo got anywhere near it. These were people with tophi on their hands and years of failed tablets behind them. For the ones who responded, uric acid dropped to levels their body had not seen in decades, and below the point where crystals stay solid there is finally room for old deposits to break down. That is the entire logic behind the target the guideline sets³.

If you are reading this page, you are probably not at the beginning of gout. You are at the hard end of it, where the pills stopped working and someone used the word infusion and it landed like a verdict. It is not one. Pegloticase exists because bodies like yours were failed by everything simpler, and none of that is a mark against you or a bill coming due for something you ate. Bring the questions on this page to your rheumatologist. Ask about the G6PD test. Ask about methotrexate. Ask what the plan is for the day the infusions stop. Walking in knowing what to ask changes what you walk out with.